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The Mediator is an evolutionarily conserved, multi-subunit complex that regulates multiple steps of transcription. Mediator activity is
regulated by the reversible association of a four-subunit module comprising CDK8 or CDK19 kinases, together with cyclin C, MED12 or
MED12L, and MED13 or MED13L. Mutations inMED12,MED13, andMED13L were previously identified in syndromic developmental
disorders with overlapping phenotypes. Here, we report CDK8mutations (located at 13q12.13) that cause a phenotypically related dis-
order. Using whole-exome or whole-genome sequencing, and by international collaboration, we identified eight different heterozygous
missense CDK8 substitutions, including 10 shown to have arisen de novo, in 12 unrelated subjects; a recurrent mutation, c.185C>T
(p.Ser62Leu), was present in five individuals. All predicted substitutions localize to the ATP-binding pocket of the kinase domain.
Affected individuals have overlapping phenotypes characterized by hypotonia, mild to moderate intellectual disability, behavioral dis-
orders, and variable facial dysmorphism. Congenital heart disease occurred in six subjects; additional features present in multiple indi-
viduals included agenesis of the corpus callosum, ano-rectal malformations, seizures, and hearing or visual impairments. To evaluate the
functional impact of the mutations, we measured phosphorylation at STAT1-Ser727, a known CDK8 substrate, in a CDK8 and CDK19
CRISPR double-knockout cell line transfected with wild-type (WT) or mutant CDK8 constructs. These experiments demonstrated a
reduction in STAT1 phosphorylation by all mutants, in most cases to a similar extent as in a kinase-dead control. We conclude that
missense mutations in CDK8 cause a developmental disorder that has phenotypic similarity to syndromes associated with mutations
in other subunits of the Mediator kinase module, indicating probable overlap in pathogenic mechanisms.The Mediator complex is a large, multi-subunit assembly
encoded by 26 genes in humans, and it regulates gene
expression in all eukaryotes. The core function of the
Mediator is to communicate developmental and physio-
logical signals from DNA-bound transcription factors to
RNA polymerase II (the enzyme responsible for the tran-
scription of all protein-coding andmost non-coding genes)
by contacting the pre-initiation complex.1,2 Regulation of
Mediator activity is, in part, achieved by the reversible
association of a four-subunit kinase module (hereafter
referred to as the ‘‘Module’’) comprising cyclin C (encoded
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MED12L, and MED13L (Figure 1). Many targets of phos-
phorylation by CDK8 have been identified.4 These include
not only the core Mediator-RNA-polymerase-II complex
(Module components [CDK8, cyclin C, MED12, MED13,
and MED13L], other Mediator subunits [MED14 and
MED26], and the C-terminal domain of RNA polymerase
II) but also many other transcriptional regulators (for
example, tissue-specific and general transcription factors,
pause or release factors, chromatin-remodeling factors,
and histone H3; reviewed by Jeronimo and Robert).2 Mir-
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Figure 1. Simplified Illustration of the
Mediator Complex and the RNA Pol II
Machinery at the Promoter of a Hypothet-
ical Gene
The CDK8 or CDK19 kinase Module
(orange) reversibly binds the Mediator
complex to regulate its activity. The Medi-
ator complex (head in blue, middle in
green, and tail in purple; additional sub-
units in light gray) bridges between gene-
specific activators (dark gray) that are
bound to regulatory elements (RE) and
general transcription machinery that com-
prises the RNA pol II (brown) and general
transcription factors (yellow). The DNA
molecule cartoon was obtained from the
Servier Medical Art; the representation
was adapted from Larivie`re et al.3many tissue- and species-specific functions, ranging from
environmental responses in yeast to organogenesis and
development in the nematode worm, fruit fly, zebrafish,
and mouse.5
In humans, mutations in the genes (MED12, MED13,
and MED13L) encoding subunits of the Module have
been implicated in developmental disorders. Mutations
in the X-linked MED12 (MIM: 300188) cause at least
three different syndromes: Opitz-Kaveggia syndrome
(also known as FG syndrome; MIM: 305450), Lujan-Fryns
syndrome (MIM: 309520), and Ohdo syndrome (MIM:
300895). These syndromes have partly overlapping clinical
features, including multiple congenital defects, facial dys-
morphic features, hypotonia, behavioral problems, and
intellectual disability (ID).6 Mutations in MED13L (MIM:
608771) are associated with a syndromic form of ID
(MIM: 616789) characterized by facial dysmorphism, ID,
speech impairment, motor developmental delay with
muscular hypotonia, cardiac anomalies, and behavioral
difficulties.7,8 Recently, mutations in MED13 (MIM:
603808) have been reported as leading to a neurodevelop-
mental disorder characterized by ID and/or developmental
delay, including speech delay; additional features that were
present in two or more affected individuals included
autism spectrum disorder (ASD), attention deficit hyperac-
tivity disorder (ADHD), optic nerve abnormalities, Duane
anomaly, hypotonia, mild congenital heart abnormalities,
and dysmorphic features.9 Here, using whole-exome or
whole-genome sequencing and by international collabora-
tion, we report de novo mutations in CDK8, which has not
been previously associated with a congenital disorder, in
12 unrelated individuals with overlapping phenotypes.
The study was initiated as part of a whole-genome
sequencing (WGS)-based investigation of craniosynostosis
in the Netherlands after approval by the board of the med-
ical ethical committee Rotterdam (MEC-2012-140). Writ-
ten informed consent was obtained from all participants
or their legal guardians. Parent-child trio-based WGS of
a proband with metopic synostosis and ID (subject 3 in
Table 1) identified a de novo c.88G>A transition in CDK8;710 The American Journal of Human Genetics 104, 709–720, April 4,this change leads to the prediction of a heterozygous
p.Gly30Ser substitution. The position of this substitution,
at an almost invariant residue within the highly conserved
glycine-rich loop of the kinase domain,9 and in which
pathogenic mutations were previously identified in other
protein kinases,22,57 led us to seek evidence for additional
pathogenic variants in CDK8 through GeneMatcher
exchange10 and from the Deciphering Developmental Dis-
orders (DDD) research study.11 The DDD study has UK
research ethics committee (REC) approval (10/H0305/83,
granted by the Cambridge South REC, and GEN/284/12
granted by the Republic of Ireland REC). Details of the
methodology we used to identify each mutation (whole-
exome sequencing [WES] in every instance except the
original index subject) are provided in the Supplemental
Material and Methods. By these means, we identified a
further 11 unrelated individuals harboring eight different
nucleotide substitutions within CDK8; one substitution
(c.185C>T encoding p.Ser62Leu) was present in five
subjects (Figure 2A and Table 1). All CDK8 variants were
constitutionally absent from the ExAC and gnomAD data-
bases of common variation (accessed November 2018).12
CDK8 is a gene that comprises 13 exons; it is located
at chromosomal region 13q12.13 and encodes a major
isoform of 464 amino acids. All seven unique substitu-
tions, and three of five instances of p.Ser62Leu, arose
de novo from unaffected parents who had correct paternity
confirmed either by comparison of trio-WES or WGS
data or by microsatellite analysis; paternal samples were
unavailable in the remaining two cases (the recurrence of
the c.185C>T transition is likely to be explained by its
position in a hypermutable CpG dinucleotide). The eight
substituted amino acids are all located within the kinase
domain, which extends between amino acids 21–335
(Figure 2B), and they are invariant in a wide range of verte-
brate CDK8 orthologs, as well as in the human paralog
CDK19; in six cases, this invariance extends to the inverte-
brates Drosophila, Aedes, and Caenorhabditis (Figure 2C).
MutationTaster predicted all eight substitutions to be
disease-causing, and SIFT and PolyPhen-2 predicted all to2019
Table 1. Clinical Features of Subjects with CDK8 Mutations
Subject # 1 2 3 4 5 6 7 8 9 10 11 12
Gender f m m f m f m m f m f m
Age (years) 9 2.9 8 7.6 0.1 0.8 16.7 12.7 6.8 5.4 12 3.5
Mutation c.79G>C c.85C>G c.88G>A c.185C>T c.185C>T c.185C>T c.185C>T c.185C>T c.291T>G c.533G>A c.578T>G c.669A>G
Substitution p.Val27Leu p.Arg29Gly p.Gly30Ser p.Ser62Leu p.Ser62Leu p.Ser62Leu p.Ser62Leu p.Ser62Leu p.Phe97Leu p.Arg178Gln p.Val193Gly p.Ile223Met
De novo yes yes yes yes yes yes NA NA yes yes yes yes
Facial
dysmorphism
þ þ þ þ þ þ þ þ  þ þ þ
Hypotonia,
motor delay,
and/or walking
difficulty
þ þ (axial) þ þ NA þ (axial) þ (bilateral
pes planus
surgery)
þ þ þ þ þ
Brain MRI or CT normal thin corpus
callosum
normal ACC NA ACC NA ACC non-specific NA normal NA
Ophthalmic:
ptosis
þ          þ 
Strabismus þ þ þ     þ    
Myopia þ þ  þ   þ (severe) þ   þ 
Impaired vision þ      þ     
Sensorineural
hearing loss
moderate moderate   NA    severe
(unilateral)
NA (glue ear) 
Intellectual
disability
mild (SEN
school)
moderate
to severe
moderate to
severe (SEN
school)
moderate NA NA; moderate
motor delay
mild to
moderate
(SEN school)
moderate
(SEN school)
moderate moderate mild
(normal
school)
NA; moderate
motor delay
Behavioral
disorder
ADHD  ASD, ADHD,
sleep disorder
ADHD,
sleep
disorder
NA NA ASD ASD, ADHD ASD happy
disposition
attention
seeking,
volatile
ASD
Epilepsy       complex
partial
 general
and focal
  
Feeding
difficulties
infancy
only
gastrostomy-
fed
congenital pyloric
stenosis
previous
gastrostomy
NA  reflux reflux,
regurgitation
reflux,
episodic
vomiting
 episodic
vomiting

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712 The American Journal of Human Genetics 104, 709–720, April 4,be damaging with the exception of the c.291T>G
(p.Phe97Leu) variant (Table S1). CDK8 is intolerant to
missense variants (z ¼ 3.81, observed/expected ratio ¼
0.34; gnomAD database)12 and exhibits high constraint
throughout the protein.13 On the basis of the DOMINO
algorithm, CDK8 was predicted to be among the top
candidate genes for which mutations are likely to manifest
with a dominant pattern of inheritance.14 The clustering
of multiple de novo substitutions localized to a single,
highly conserved domain of the protein provides a strong
pathogenicity signature, as has been described for several
other genes including the cyclin-dependent kinase
(CDK)-encoding CDK13.11,15,16
We assessed the phenotypes of the 12 subjects, seven
males and five females aged 0.1–16.7 years at the last clin-
ical assessment, with CDK8 substitutions by using a stan-
dardized spreadsheet-based questionnaire (summarized in
Table 1; full details can be found in Table S2, and case
reports can be found in the Supplemental Note). Most
affected children were born after unremarkable pregnan-
cies, at or near term, with a birth weight within the normal
range, and they did not require neonatal resuscitation,
although around half required hospitalization after birth
because of jaundice, seizures, laryngomalacia, or cardiac
problems. More consistent difficulties emerged in early in-
fancy: hypotonia (noted in 11/12 subjects) was frequently
evident, and it later manifested as motor delay and some-
times persistent problems in walking. Mild to moderate
developmental delay was universal, and older children
had ID which ranged from mild (two cases) to moderate–
severe (two cases); most were in the moderate range (five
cases). Most children attended schools for special educa-
tional needs, but one had mainstream education. Behav-
ioral symptoms were prominent: seven of ten of the older
individuals had formal diagnoses of autism spectrum disor-
der (ASD) and/or attention deficit hyperactivity disorder
(ADHD). The head circumference was normal except in
one subject, who had mild macrocephaly (þ2.21 standard
deviations [SD]); magnetic resonance imaging (MRI) of the
brain showed agenesis or thinning of the corpus callosum
in four subjects, including the macrocephalic individual.
Two individuals had seizures, but brain imaging was either
normal or was not available. Three individuals had moder-
ate-severe sensorineural hearing loss; ophthalmological
abnormalities were frequent, including myopia (n ¼ 6),
eyelid ptosis (n ¼ 2), and/or strabismus (n ¼ 4), and these
were associated with marked visual impairment in two
children. Congenital heart defects (CHDs) were present
in six of the twelve subjects; the defects were classified17
as left ventricular obstruction (n ¼ 3), conotruncal defects
(n ¼ 1), and other (n ¼ 2). Present congenital gastrointes-
tinal problems were ano-rectal abnormalities (n ¼ 2) and
pyloric stenosis (n ¼ 1); two additional infants required
feeding via gastrostomy tube. In later childhood, gastro-
esophageal reflux or episodic vomiting were significant
management issues in four individuals. Facial dysmor-
phism was identified in 11 subjects; this was not2019
Figure 2. Mutations in CDK8 and Conservation of Substituted Residues
(A) Localization of mutations (in red) in a schematic representation of human CDK8 (exon numbering on GenBank: NM_001260.2).
(B) A cartoon of the humanCDK8 (based onUniProt: P49336) showing the location of the protein kinase domain (21–335; gray box) and
the eight different CDK8 substitutions identified in this work (below, in red). Note that the p.Ser62Leu substitution was identified in five
unrelated subjects. Relevant functional elements are depicted in dark boxes. Note the Gly-rich loop (27–35); Lys52, a catalytic residue
that interacts with the triphosphate of ATP in the active site; Asp151 within the conserved His-Arg-Asp (HRD) motif (at the catalytic
loop), which is directly involved in catalysis; and Asp173, which is included in the Asp-Met-Gly (DMG)motif (at the activation segment)
required for chelation of the magnesium ion involved in the catalysis. Substitution of Asp173 is widely used as a catalytically inactive
kinase-dead form of CDK8 (p.Asp173Ala).
(C) A multiple-protein sequence alignment of CDK8 and CDK19 at the positions of the identified substitutions in CDK8. Abbreviations
are as follows: Hs¼ human,Mm¼mouse, Xt¼western clawed frog, Dr¼ zebrafish, Dm¼ fruit fly, Ae¼ yellow fevermosquito, and Ce¼
nematodeworm. The positions of the CDK8 de novomissense variants are indicatedwith a red arrow at the top of the sequences. Black- or
gray-shaded amino acids indicate identical or similar residues compared to the human CDK8 sequence, respectively. Below the align-
ments, an asterisk (*) indicates positions that have a single, fully conserved residue, whereas a colon (:) indicates conservation between
groups of similar properties. Additional relevant features present in these sequences (Gly-rich loop, DMGmotif, and the Asp173 residue,
mutated in the kinase-dead mutant) are also depicted.characteristic, although arched eyebrows, epicanthic folds,
prominent eyes, a prominent nasal tip or long columella, a
long philtrum, wide or open-mouth posture, prognathism,
and low set and prominent ears were highlighted in two or
more subjects (Figure 3 and Table S2). The subjects’ stature
was within the normal range except in one individual,
who hadmild short stature (2.53 SD). Apart from the me-
topic synostosis present in the index individual, no other
individuals had craniosynostosis.
We assessed the probable effects of the eight individual
amino acid substitutions on the CDK8 kinase domain
by examining available protein structures (Figure 4). Three
of the substitutions (c.79G>C [p.Val27Leu], c.85C>G
[p.Arg29Gly], and p.Gly30Ser) are clustered in the Gly-
rich loop (amino acids 27–35), a highly conserved pro-The Ametein-kinase motif with a critical role in ATP binding
and in the phosphoryl-transfer reaction.21–23 Substitutions
within this motif affect kinase activity and, in other
kinases, have been described as pathogenic mutations
responsible for various congenital disorders.15,22,24,25
Within the three-dimensional structure, all CDK8 substitu-
tions either affect amino acids surrounding the ATP-bind-
ing pocket (Figure 4B) or are in contact with key functional
amino acids; for example, the p.Ile223 residue is not
directly part of the ATP-binding site but is within interact-
ing distance of p.Lys153, which directly binds to the ATP
phosphate in the input structural model. The recurrently
mutated p.Ser62 residue is located in the aC-helix,26
the conformation and interactions of which are impor-
tant for CDK8 activity.27 Two substitutions, c.533G>Arican Journal of Human Genetics 104, 709–720, April 4, 2019 713
Figure 3. Clinical Pictures of Subjects with CDK8 Mutations
Subjects (left to right): 1 (c.79G>C [p.Val27Leu]) aged 16 months, 3 (c.88G>A [p.Gly30Ser]) aged 4 years (postoperative after surgery to
correct metopic synostosis), 4 (c.185C>T [p.Ser62Leu]) aged 9 years, 10 (c.533G>A [p.Arg178Gln]) aged 9 years, and 11 (c.578T>G
[p.Val193Gly]) aged 2.5 years.(p.Arg178Gln) and c.578T>G (p.Val193Gly), affect amino
acids located in the activation segment,26 which interacts
with other key amino acids (Figure 4B). One of the substi-
tutions (p.Phe97Leu) affects the ‘‘gatekeeper’’ p.Phe97 of
CDK8. Mutations in the gatekeeper residue of kinases
have emerged as a key mechanism by which cancer cells
develop resistance to treatment,28 highlighting the impor-
tance of the gatekeeper residue controlling the back cavity
of the ATP site.29
To gain further insights into the effects of the muta-
tions, we conducted molecular-dynamics simulations for
wild-type (WT) and two selected CDK8 substitutions,
p.Ser62Leu, and p.Arg178Gln, in complex with cyclin C
and in the presence of ATP. The overall CDK8 protein
structure and organization was predicted to be unchanged
in the mutant models compared to in the WT. However,
we found that in addition to impacting the ATP-binding
site, the mutants were also predicted to induce pro-
nounced structural changes in the substrate-binding site
(Figure 4C). In particular, the substrate-binding site of
the WT CDK8 protein can adopt more open conforma-
tions than its mutated counterparts, potentially allowing
substrates to bind more closely in the vicinity of ATP in
the WT protein.
To determine whether the CDK8 kinase domain substi-
tutions had caused structural changes and/or affected
the ability to bind ATP, we purified CDK8 kinase Modules
that were isolated from cells by immunoprecipitation after
the expression of WT or mutant-tagged-CDK8 (Figures 5A
and S1), and we recorded protein-melting curves in the
absence or presence of ATP (Figure 5B). In the absence of
ATP, the thermal stability of mutant proteins ranged
from indistinguishable to increased in comparison to the
WT protein. Moreover, the stability of most mutant pro-
teins was increased by the addition of ATP, in some cases
to a greater extent than occurred in the WT protein.
Together these results suggest that none of the substitu-
tions cause gross mis-folding of the protein, and most or
all are still able to bind ATP.
Finally, we investigated how the CDK8 substitutions
affected the kinase activity by measuring phosphorylation
of one of its well-validated targets: p.Ser727, of the human714 The American Journal of Human Genetics 104, 709–720, April 4,transcription factor STAT1.30–34 We used a CRISPR-Cas9-
engineered human cell line (SW620 colorectal carcinoma
cells) that lacks both CDK8 and CDK19 (M.J. Ortiz-Ruiz
et al., Cancer Res., abstract). These cells exhibited baseline
STAT1-Ser727 (pSTAT1) phosphorylation that was substan-
tially increased when WT CDK8 was transiently re-ex-
pressed (Figure 6). We performed site-directed mutagenesis
to introduce the eight observed variants into CDK8 cDNA
(Supplemental Material and Methods), which we trans-
fected into the CDK8 and CDK19 CRISPR double-knockout
cells. We observed that the cellular levels of pSTAT1 were
reduced to a statistically significant extent, compared to
WT, in all mutant-transfected cells (Figure 6). For most mu-
tants, the reduction in kinase activity was similar to that in
the catalytically inactive CDK8 kinase-dead (p.Asp173Ala)
mutant we used as a control, but in two mutants (p.Phe97-
Leu and [c.669A>G] p.Ile223Met), an intermediate level of
phosphorylation (63% and 51% in comparison to the
WT, respectively), was observed.
Collectively, our genetic and functional assessments
provide strong evidence for a previously unrecognized (to
our knowledge) clinical disorder caused by heterozygous
missense substitutions located in the kinase domain of
CDK8. All eight distinct mutations were shown to have
arisen de novo from unaffected parents (Table 1) and ex-
hibited a similar combination of molecular characteristics.
All clustered within the kinase domain (Figure 2) and were
concentrated around the ATP binding pocket (Figure 4);
none was associated with gross protein instability, and all
retained the ability to bind ATP (Figure 5). Finally, all ex-
hibited attenuated kinase activity in a previously validated
assay of STAT1-phosphorylation, although the magnitude
of the effect was diminished for two substitutions
(Figure 6), suggesting partial retention of activity in those
cases. Of note, the CDK8 mutant proteins maintained
their ability to bind cyclin C, similar to the ability of the
kinase-dead mutant (Figures 5A and S1, and as previously
described).35 The CDK8 kinase-dead mutant was previ-
ously shown to form a stable Module, although the inac-
tive kinase was unable to phosphorylate its targets.35,36
Concordant with these molecular observations was a
relatively consistent phenotypic presentation (Figure 3,2019
Figure 4. Location and Effect of CDK8
Substitutions on the Protein Structure
(A) Overall structure of CDK8 (light gray)
in complex with cyclin C (dark gray).
ATP (blue) was modeled into the CDK8
DMG-in crystal structure (PDB: 4F7S)18
using aligned CDK9 (PDB 3BLQ).19 Re-
gions not previously resolved in the crystal
structure have been modeled using Molec-
ular Operating Environment (MOE).20
(B) Amagnified view of the catalytic region
of the CDK8 kinase domain. The Mg2þ is
shown as a green sphere. Amino acids
at which mutations have been identified
are colored in orange (except Ser62 in red
and Arg178 in yellow), and relevant,
potential interaction partners in the input
structure are shown as sticks. Ile223 is in
close proximity (double-headed arrow) to
the Lys153 involved in interaction with
ATP-phosphate. Arg178 forms a hydrogen
bond with Tyr32 (Gly-rich loop) and inter-
acts ionically with the catalytic Asp151.
(C) A magnified overlay of the wild-type
(WT) and mutant molecular-dynamics
simulations of CDK8 (light gray) in com-
plex with cyclin C (dark gray) in the pres-
ence of ATP (blue spheres). The areas dis-
playing the most pronounced structural
differences within the substrate binding
site are colored (blue: WT, red: p.Ser62Leu,
and yellow: p.Arg178Gln).Table 1, Supplemental Case Reports, and Table S2). Hypo-
tonia was usually evident in infancy and, in children old
enough for assessment, learning disability was universal
and most commonly classified as moderate; most but
not all children were attending schools for special
educational needs. Associated behavioral problems, which
were frequent and added to the management issues for
these children, included formal diagnoses of ASD and
ADHD, sleep disorders, and episodic vomiting. Dysmor-
phic facial features, including arched eyebrows, a bulbous
or upturned nose, and hypotonic facies, were frequent;
however, these do not constitute a consistent or easily
recognizable phenotype. Six of 12 subjects had congenital
heart malformations, including at least three requiring
corrective surgery. Additional medically significant fea-
tures are documented in Table 1. The high frequency
of diagnosis of ASD, ADHD, and CHD in these chil-
dren is of note because CDK8 mutations have not
previously been highlighted in genetic screens of those
disorders;17,37 this might be because the target size for
mutations of CDK8 (missense substitutions surrounding
the ATP-binding pocket) is relatively small. Although the
mutation in our index subject, who had metopic synosto-
sis, was originally identified in a genetic study of craniosy-
nostosis, none of the 11 other subjects identified had thisThe American Journal of Humanphenotype. It is unclear whether the
co-occurrence of the mutation and
craniosynostosis is causally linked(potentially through the adverse effect of the mutation
on brain development)38 or is coincidental.
Inmore than two decades since CDK8was first identified
in independent studies of the yeast Saccharomyces cerevisiae
(from screens for the stabilization of meiotic mRNAs
[Ume5]39 and suppression of an RNA polymerase II
C-terminal domain mutation [Srb10]),40 a large literature
has accumulated about its functions.5,41 As described
above and illustrated in Figure 1, CDK8 encodes a kinase
component of the Module, a four-subunit complex that
binds to the Mediator and regulates its activity. Many
fundamental uncertainties remain about its function, for
example how the association and dissociation of the Mod-
ule with the Mediator is regulated, how the Module regu-
lates gene expression both positively and negatively, and
the extent to which kinase activity per se is required for
these functions.2 Previous studies of human CDK8 have
mostly focused on its potential as a therapeutic target in
cancer, on the basis of the observation that amplifications
of CDK8 are frequent in colon cancer.42 Although effective
CDK8 inhibitors have been developed, to date they have
exhibited unacceptable toxicity.31,32 This toxicity might
reflect the essential function of CDK8 for normal develop-
ment, as shown by the pre-implantation lethality of ho-
mozygous-null Cdk8mutations in the mouse; importantlyGenetics 104, 709–720, April 4, 2019 715
Figure 5. Immunoprecipitation of CDK8
and Thermal Stability Assay
(A) Lysates from HEK293T cells transiently
transfected with Myc-FLAG-tagged wild-
type (WT) or mutant CDK8 constructs
were used for immunoprecipitation with
anti-FLAG antibody or mouse IgG isotype
control antibody. The immunocomplexes
were purified with protein G magnetic
beads. CDK8 was released by adding
FLAG peptide, and an aliquot of the
eluted fraction was saved for immunoblot
analysis with anti-Myc or anti-cyclin C
(CycC) antibodies.
(B) A thermal stability assay of the eluted
fractions incubated in the absence or pres-
ence of ATP and heated individually at
different temperatures (gradient between
50–82C). Virtual blot views of results
for WT and the mutants are shown. For
each CDK8 construct, the red arrowhead
indicates 50% reduction of the CDK8
signal compared to the signal at the lowest
temperature.in relation to the discussion below, heterozygous animals
were reported to be normal and fertile.43
If one focuses on the developmental role of CDK8, our
observations show that although a single WT CDK8 allele
is sufficient for survival, heterozygosity for a mutant allele
that encodes a missense substitution of the kinase domain
causes pleiotropic developmental abnormalities. Broadly
speaking, heterozygous mutations might be associated
with abnormal phenotypes through one of three mecha-
nisms: haploinsufficiency, gain of function, and domi-
nant-negative activity.44 When haploinsufficiency occurs,
many mutations are expected to be either truncating or
partial or whole-gene deletions. Deletions involving
CDK8 are very rare, and those recorded involve many
other genes, so they are essentially uninformative.
Although our gene-matching methods would not detect
deletions, they were unbiased with regard to the nature
of the intragenic mutation. It was previously reported
that 381 of 706 de novo mutations in haploinsufficient
genes were truncating,11 so the finding that 11/11
(excluding the index subject) intragenic nucleotide substi-
tutions encode missense changes diverges significantly
from a haploinsufficiency pattern (p ¼ 0.0004). Moreover,
human CDK8 is only moderately constrained to loss of
function (probability that the gene is intolerant to a loss
of function (LoF) mutation (pLI) ¼ 0.38, gnomAD data-
base); it has six (out of 250,000) bona fide truncating
alleles listed in gnomAD, suggesting that such alleles
exist at low frequency in the normal population. Overall,
haploinsufficiency appears unlikely to be the underlying716 The American Journal of Human Genetics 104, 709–720, April 4, 2019mechanism that explains the CDK8-
mutation-associated phenotype.
Instead, our experimental observa-
tions indicate that the mutations
retain ATP binding yet lose ordiminish the ability to phosphorylate a well-established
substrate, STAT1. This might result from reduced ATP
catalysis and phosphoryl-transfer and/or altered substrate
binding resulting from reduced accessibility of the sub-
strate-binding site predicted by the dynamic modeling
(Figure 4). Notably, CDK8 (together with its paralog
CDK19) are the only components of the Module with cat-
alytic activity, so we predict that up to 50% of CDK8 mod-
ules could be present in a kinase-inactive, non-productive
state. The consequence of this would then depend on the
extent to which supply of the catalytically-active Module
was rate-limiting to key cellular processes in particular
developmental contexts. The notion that the supply of
active Modules might frequently be limiting is supported
by the observation that all six other genes encoding com-
ponents of the human Module (CCNC, CDK19, MED12,
MED12L, MED13, and MED13L) exhibit very strong
constraint against loss-of-function variation (pLI ¼ 1,
observed/expected scores 0–0.11), indicating that reduc-
tion of any Module component by 50% impairs survival
(by contrast, only three of 26 genes encoding other com-
ponents of the Mediator exhibit pLI ¼ 1; Table S3).
Together, these observations currently support a domi-
nant-negative mechanism of pathogenesis for CDK8
substitutions. Similar patterns of localized missense sub-
stitutions have been highlighted as a signature of domi-
nant-negative activity, including in the kinase domain
of another cyclin-dependent kinase, CDK13.15,16 More-
over, overexpression of the kinase-dead mutants of
different CDKs (CDK1, CDK2, CDK3, or CDK9) in human
Figure 6. Effect of CDK8 Substitutions on STAT1-Ser727 Phosphorylation
SW620 CDK8 and CDK19 double-knockout cells were transiently transfected with FLAG-tagged wild-type (WT) or mutant CDK8 con-
structs, and the cellular levels of pSTAT1-Ser727 were determined as a readout of CDK8 activity. The CDK8 kinase-dead (p.Asp173Ala)
mutant was used as a control for defective kinase activity. Whole-cell lysates from non-transfected cells (E lane) or from transfected cells
were collected, and equal amounts of total protein were subjected to immunoblotting with anti-phospho-STAT1-Ser727 and anti-STAT1
(total) antibodies. Anti-FLAG was used to detect the overexpressed CDK8 constructs, and GAPDHwas used as loading control. Represen-
tative blots are shown in the two left panels. For the quantification (right panel), the relative intensities of the bands were taken as a ratio
of the phosphorylated STAT1-Ser727 (pSTAT1) over the total amount of STAT1 (STAT1) and then plotted against the WT, which
was normalized to one, for each individual blot. The values shown represent means 5 SEM from five independent experiments. The
results were compared to WT and analyzed by one-way ANOVA with Dunnett’s multiple-comparisons test; * p % 0.05, ** p % 0.01,
and *** p% 0.001.cells was previously observed to act by dominant-negative
mechanisms.45–47 We explored the mechanism directly
by mixing equal amounts of the WT and p.Ser62Leu
CDK8 constructs and measuring STAT1 phosphorylation,
but the observed reduction in phosphorylation in mixed
samples did not obviously deviate from a linear response
(data not shown); hence, further experiments will be
required to support or refute the dominant-negative
hypothesis.
Previous observations that mutations in MED12
(X-linked; mostly hemizygous) and MED13L (heterozy-
gous) were associated with generally similar phenotypes,
including ID, hypotonia, and other congenital anoma-
lies,6–8,48 led to the coining of a so-called ‘‘mediatorpathy’’
phenotype.49 More recently, heterozygous mutations
in MED13 were also considered to fit this pattern.9
Interestingly, in the case of MED12, it was demonstrated
experimentally that the substitutions p.Arg961Trp and
p.Asn1007Ser (causing FG and Lujan syndromes,
respectively), exhibit impaired recruitment of CDK8 onto
GLI3-target gene promoters, leading to hyperactivated
GLI3-dependent SHH signaling.50 Here, we find that the
major clinical features (including moderate ID, hypotonia,
ASD, ADHD, and CHD) associated with CDK8 muta-
tions again show substantial phenotypic overlap, lending
further support to the general concept of a Module-related
syndrome. By contrast, relatively fewer (to date, up to four
replicated: MED17, MED20, MED23, and MED25) muta-
tions in the other 26 non-Module components of the
Mediator have been described; bi-allelic mutations in
MED17 or MED20 (both members of the Mediator’s
Head) produce progressive cerebral and/or cerebellar
atrophy, whereas bi-allelic mutations in MED23 or
MED25 cause syndromic or non-syndromic ID (summa-
rized in Table S3).The AmeIn summary, therefore, our observations support the
proposed clustering of developmental disorders related to
perturbed function of the Module (‘‘Mediator kinase mod-
ulopathy’’). Given the pleiotropic actions of the Module,
many mechanisms, including defects in key develop-
mental signaling pathways, might lead to these pathol-
ogies. For example, the severe developmental defects iden-
tified in embryos with Med12 hypomorphic mutations are
produced by impairment of the canonical and Wnt/PCP
signaling pathways;51 analogously, CDK8 has a pivotal
role as a regulator of several additional signaling pathways,
includingWNT, TGFb/BMP, STAT1, SHH, and NOTCH.52,53
Thus, a disruption of the proper activity of CDK8 could
modify any of these developmental signaling networks.
Although the idea of a Mediator kinase modulopathy
as a pathogenic entity is attractive, several cautions are
necessary. Genetic evidence from Drosophila formally
demonstrates the non-equivalence of different Module
components, on the basis of differences in the respective
phenotypes when comparing mosaic knockouts for a
Cdk8-Ccnc pair compared with a Med12-Med13 pair.54
This situation is compounded for vertebrates, in which
paralogous pairs exist for three of the four Module sub-
units. Indeed, the single described disruption (caused by
a chromosomal inversion) of the CDK8 paralog CDK19
was associated with a different phenotype that comprised
microcephaly, congenital bilateral falciform retinal folds,
nystagmus, and learning disability;55 however, the func-
tions of CDK8 and CDK19 are known to be divergent.56
Finally, it remains uncertain to what extent, and in which
circumstances, Module activity might be kinase-indepen-
dent because these functions would likely be unaffected
by the mutations described here.2 Further work on the
structure and function of the Mediator will doubtless
shed light on these issues.rican Journal of Human Genetics 104, 709–720, April 4, 2019 717
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Supplemental Note: Case Reports 
 
Subject 1 
This girl was born after an uneventful pregnancy. Immediately after birth a ptosis of 
the right eye was noticed. During the first year of life feeding difficulties, a vertical gaze 
palsy, hypotonia and motor delay became apparent. Pediatric neurological 
examination also showed facial weakness and a congenital myasthenic syndrome was 
suspected. A pyridostigmine treatment trial resulted in a mild, temporary improvement. 
Language development was also delayed, with nasal speech and a hoarse voice. She 
has a sensorineural hearing loss (right: 35 dB, left: 22 dB). Because of a mild 
intellectual disability (ID), visual impairment and attention deficit hyperactivity disorder 
(ADHD), she visits a special educational needs school. Behavioral problems include 
ADHD, tantrums and anxiety. Until the age of 6 yr she has had recurrent febrile 
episodes. 
Array-CGH was normal. Clinical whole exome sequencing (WES; performed in-house 
as a parent-child trio) did not identify any known pathogenic variants; however the de 
novo c.79G>C (p.Val27Leu) substitution in CDK8 was highlighted as a variant of 
unknown significance (VUS) and submitted to GeneMatcher. 
An additional de novo missense variant was identified in the CACNA1A gene 
(gnomAD: missense Z = 6.19, o/e = 0.55; loss-of-function [LoF] pLI = 1.00, o/e = 0.05). 
The CACNA1A NM_023035.2:c.2570G>A (p.Arg857His) variant is not present in 
gnomAD. Mutations affecting the CACNA1A gene are responsible for the autosomal 
dominant epileptic encephalopathy, early infantile (MIM: 617106), episodic ataxia, 
type 2 (MIM: 108500), migraine, familial hemiplegic (MIM: 141500) or spinocerebellar 
ataxia 6 (MIM: 183086) disorders. This variant has not been identified before in any of 
these disease cohorts. Although the missense variant is located outside the intervals 
of the transmembrane domains (I-IV), in a region apparently more tolerant to missense 
variation,1 we cataloged this as a VUS. 
Additionally, a de novo mosaic variant (present in ~20% of cells) was identified in the 
HDAC9 gene (gnomAD: missense Z = 2.27, o/e = 0.73; LoF pLI = 1.00, o/e = 0.13). 
 
 
The HDAC9 NM_178423.1:c.646C>T (p.Arg216*) variant is not present in gnomAD. 
Although it was suggested that HDAC9 deletions could represent a risk factor for 
autism, ID and schizophrenia associated with incomplete penetrance/variable 
expressivity,2 the involvement of HDAC9 mutations in congenital disorders has not 
been defined. 
 
Subject 2 
This 3-year old male was born at 37+5/7 weeks by forceps-assisted vaginal delivery 
after an uncomplicated pregnancy. Apgar scores were 7 and 8 at 1 and 5 min, 
respectively. The neonatal course was significant for respiratory distress thought to be 
secondary to meconium aspiration, hyperbilirubinemia requiring phototherapy, and 
feeding difficulty. He did not pass his newborn hearing screen, which was initially 
thought to be related to antibiotics given as part of sepsis rule-out during his neonatal 
intensive care unit (NICU) course. 
At 7 weeks of age, he was admitted for failure-to-thrive. He also had increased 
respiratory effort during feeds as well as oral motor difficulties, reflux, and inefficient 
suck. He was found to have laryngomalacia and a sleep study demonstrated severe 
obstructive sleep apnea requiring supplemental oxygen. A nasogastric tube was also 
placed for supplemental nutrition. During this hospitalization he was noted to have low 
tone and subtle dysmorphic features prompting further work-up for a neurologic and 
genetic disorder. Metabolic screening (plasma amino acids, urine organic acids, 
acylcarnitine profile, lactic acid and creatine kinase) was unrevealing, as were a single 
nucleotide polymorphism (SNP) chromosomal microarray and methylation studies for 
Prader-Willi and Angelman syndromes. Magnetic resonance imaging (MRI) of the 
brain at 5 mo showed nonspecific white matter abnormalities including a thin corpus 
callosum with bilateral posterior supratentorial and perihippocampal white matter 
volume loss, with possible hypomyelination.  
He went on to demonstrate significant delays in his development in all domains. An 
evaluation at 12-13 mo showed age equivalencies of 3-4 mo for gross and fine motor 
skills, and 6-7 mo for social development. At the most recent assessment (aged 3 yr) 
he was able to roll and hold his head up, as well as sit propped up in a chair but not 
 
 
unsupported. He could reach for toys and grasp with a full hand but had no pincer 
grasp. He says “mama” and “papa” but no other words, he responds to his name and 
tracks well. On general examination he is dysmorphic with brachycephaly and a tall 
and broad forehead, shallow orbits with the appearance of proptosis, low set ears with 
overfolded superior helices bilaterally and a tented mouth that is held open (low facial 
tone). His growth parameters are all within the normal range. Neurologic exam showed 
an alert toddler with no verbal output, good tracking and attention to sound. He was 
able to follow some simple commands from parents with prompting. He has marked 
global hypotonia with normal reflexes and no clonus, as well as frequent non-
purposeful complex stereotypic movements of his distal extremities.  
He is currently followed by multiple specialties, including ophthalmology for 
nystagmus, high myopia, and optic nerve cupping of both eyes; neurology; audiology 
for sensorineural hearing loss; and an aerodigestive team for feeding (he now has a 
G tube in place for nutrition) as well as respiratory concerns. He no longer requires 
oxygen and has had some improvement in swallowing, however aspiration continues 
to be a risk. He has had a normal echocardiogram. 
As part of his diagnostic work-up, trio whole exome sequencing was performed by 
GeneDx, which identified a de novo missense variant of uncertain significance in the 
gene CDK8 (c.85C>G, p.Arg29Gly). 
 
Subject 3 
This 9-year old boy was born as the second child, after an uneventful pregnancy of 
non-consanguineous parents, with a severe trigonocephaly, a perimembranous 
ventricular septal defect with a double orifice mitral valve, and pyloric hypertrophy for 
which surgery was required. Measurements of thyroid function were normal. No 
intracranial anomalies were seen on the preoperative CT scan and an ultrasound of 
the kidneys was normal. An uneventful fronto-supraorbital reconstruction was 
performed at 10 mo. 
His development was delayed and he started walking at age 2.5 yr and talking at age 
4 yr. At 8 yr an IQ of 55 was measured; his social behavior was like a 12- to 18-month 
old. He had trouble going to sleep for which melatonin was used. The diagnosis of 
 
 
autism spectrum disorder (ASD) and of ADHD was made; the ADHD worsened in 
response to Ritalin and was thus stopped. On ophthalmological review he had 
intermittent exotropia and surso adductorius in both eyes with V-motility. Vision was 
0.5 for both eyes but somewhat unreliable due to a lack of concentration.  
Whole genome sequencing (WGS), performed on the parent-child trio as part of a 
research study of craniosynostosis, did not identify any known pathogenic variants. 
Three de novo substitutions were identified, of which the c.88G>A (p.Gly30Ser) 
mutation in CDK8 was selected for further investigation. 
Two additional de novo missense variants were identified in the TRPM2 (gnomAD: 
missense Z = -0.21, o/e = 1.02; LoF pLI = 0.00, o/e = 0.89) and COL3A1 (gnomAD: 
missense Z = 4.40, o/e = 0.59; LoF pLI = 1.00, o/e = 0.04) genes. The TRPM2 
NM_003307:c.2557G>A (p.Glu853Lys) variant has been observed in gnomAD 
(6/281772, 2.129e-5). Additionally, in gnomAD there are additional variants affecting 
the same amino acid (p.Glu853Gln, p.Glu853Asp). We considered the variant unlikely 
to have clinical significance. The COL3A1 NM_000090, c.2621T>C (p.Phe874Ser) 
variant is not present in gnomAD, although there is a variant affecting the same amino 
acid (p.Phe874Cys). Mutations affecting the COL3A1 gene are responsible for the 
autosomal dominant Ehlers-Danlos syndrome, vascular type (MIM: 130050). This 
variant has not been identified before in Ehlers-Danlos syndrome cohorts. Although 
this missense variant differs from the typical signature of causative variants identified 
in Ehlers-Danlos syndrome,3 we cataloged this as a VUS. 
 
Subject 4 
This girl, currently aged 7.6 yr, was born to a 38 year old G2 P1 mother. The pregnancy 
was complicated by pneumonia, for which she took antibiotics. The prenatal 
ultrasound revealed a hypoplastic left heart and agenesis of the corpus callosum. She 
was born by caesarean section at 38 weeks’ gestation, and was small for gestational 
age (birthweight 2.3 kg, length 47 cm). She was cyanotic and hypoxic at birth, and 
underwent cardiac surgery at 4 days of age via a Norwood procedure. She has 
subsequently undergone two additional cardiac surgeries, a bi-directional Glenn 
procedure aged 4 mo and a Fontan procedure aged 4 yr. She had dysphagia requiring 
a gastrostomy tube aged 7 mo, but now eats completely by mouth. She wears glasses 
 
 
for myopia and has normal hearing. A brain magnetic resonance imaging (MRI) 
confirmed agenesis of the corpus callosum and mild ventriculomegaly.  
She has a history of failure to thrive and remains small for her age, with her height at 
-2.53 SD, weight at -1.92 SD, and a normal occipito-frontal circumference (OFC). She 
is mildly dysmorphic, with bilateral epicanthal folds, prominent eyes, a small nasal tip 
with a short columella and a broad nasal base, broad thumbs and broad, laterally 
deviated great toes, hypoplastic distal phalanges of all toes, planovalgus feet, and mild 
hypotonia. 
Her development has been globally delayed. She did not roll or sit until 18 mo, walked 
at 4 ½ yr, said her first word at 4 yr, and spoke in sentences at 6 yr. She is in special 
education classes at school and receives speech, physical, occupational, 
developmental and music therapies. She has ADHD, with a sweet personality, but is 
sometimes aggressive, and has a severe sleep disorder. 
Clinical WES was performed on the parent-child trio by GeneDx and did not identify 
any known pathogenic variants; however the de novo c.185C>T (p.Ser62Leu) 
substitution in CDK8 was reported as a VUS and submitted to GeneMatcher. 
 
Subject 5 
This individual is a 2-day old boy born after an uneventful pregnancy at 41+0 weeks’ 
gestation via vaginal delivery after induced labor. He is the second child of unrelated 
parents. At birth he weighed 3120 grams. He was born with an ano-rectal 
malformation, an atrial septal defect, ventricular septal defect (VSD), bicuspid aortic 
valve, and a hypoplastic aortic arch. On examination no dysmorphic features were 
present except for low-set ears, which were slightly rotated backwards. He was lost to 
follow-up at the age of 6 mo, at which time he was unable to sit independently.  
SNP-array showed a paternally inherited duplication at 7q11.21 (chr7:63,352,782-
63,856,505; hg19)x3 considered likely to be a benign finding. Clinical WES was 
performed on the parent-child trio at the same institution as for Subject 1. Although 
this did not identify any known pathogenic variants, the de novo c.185C>T 
(p.Ser62Leu) substitution in CDK8 was highlighted as being of potential significance. 
 
 
An additional de novo missense variant was identified in the TRAF6 gene (gnomAD: 
missense Z = 2.85, o/e = 0.54; LoF pLI = 1.00, o/e = 0.05). The TRAF6 NM_004620.3: 
c.1193C>T (p.Pro398Leu) variant is not present in gnomAD. The variant does not 
affect any of the three zinc finger domains, although is located within a region that is 
likely involved in protein interactions. The implication of mutations of TRAF6 in 
congenital disorders is not well defined so far. A de novo LoF (frameshift mutation 
located in the last exon of the TRAF6) was described in one proband with hypohidrotic 
ectodermal dysplasia,4 whereas a homozygous deletion affecting the 5′UTR of TRAF6 
was recently identified in a subject with an atypical form of osteopetrosis.5 We 
cataloged the identified variant as a VUS. 
 
Subject 6 
This individual is a 10 mo female, born to white parents aged 28 yr (mother) and 39 yr 
(father), and was initially referred for clinical genetics evaluation at the age of 5 mo 
owing to agenesis of the corpus callosum, aortic coarctation and global developmental 
delay. She has one healthy older sister. The mother had two previous miscarriages. 
On examination she had a large head (occipito-frontal circumference [OFC] 47.5 cm, 
+2.21 SD), with hypertelorism, sparse eyebrows, long columella and downturned 
corners of the mouth, with axial hypotonia and hypertonia of the lower extremities. 
Initial workup included a normal karyotype and SNP array. She underwent aortic 
coarctation repair aged 5 mo with a good result. When she was last evaluated at the 
age of 10 mo she had made some developmental progress, but was significantly 
delayed with milestones equivalent to 5 mo (rolling over, sitting with support). 
Clinical WES was performed on the parent-child trio by GeneDx and did not identify 
any known pathogenic variants; however the de novo c.185C>T (p.Ser62Leu) 
substitution in CDK8 was highlighted as a VUS and submitted to GeneMatcher. 
 
Subject 7 
This male subject is the only child of his parents. At birth he was noted to have low set 
ears, redundant skin in the neck, lymphedema of the hands and feet, undescended 
testes, and echocardiography showed tetralogy of Fallot. An initial diagnosis of 
 
 
Noonan Syndrome was proposed. He underwent cardiac surgery at 9 mo. Assessment 
at 7 mo demonstrated mild delay of motor development and he continued to have low 
muscle tone throughout childhood. By 8 yr he had developed complex partial seizures 
and migraines, both improved with valproic acid. He had mild-moderate ID and was in 
special educational classes. 
Genetic testing including array-comparative genomic hybridization (array-CGH), 
CHD7 and KAT6B did not reveal any pathogenic mutations. 
Assessment at the age of 16 yr demonstrated persistence of low muscle tone, 
including low oral muscle tone with dribbling. He had an abnormal narrow palate with 
marked dental decay. He has had bilateral lateral column lengthening and serial 
plaster casting for pes planus and can walk for approximately 2 miles. He is registered 
as partially sighted due to a severe myopia. He attended school for children with 
special educational needs. At the age of 22 yr he was given a diagnosis of childhood 
autism. 
He was enrolled as a singleton into the Deciphering Developmental Disorders (DDD) 
WES project, which did not identify any pathogenic variants of known clinical 
significance. The heterozygous c.185C>T (p.Ser62Leu) variant in CDK8 was identified 
through DDD CAP#144 and subsequently confirmed on dideoxy-sequencing to be 
present in the subject and absent in his mother. The father was unavailable for 
analysis. 
 
Subject 8 
This child is the second of two boys born to unrelated parents. The older brother has 
epilepsy but no other medical problems. The father (who was not available for genetic 
testing) is well; the mother, who has moderate learning difficulties, tested negative for 
the CDK8 c.185C>T variant identified in her son; there is no other family history of 
learning problems. 
He was born after an uneventful pregnancy at 41 weeks’ gestation with a birth weight 
of 4.3 kg. No neonatal problems were reported. He was seen by a pediatrician at 5 mo 
because of developmental delay, marked hypotonia and brachycephaly with marked 
flattening over the right occiput. At almost 2 yr, he had marked head lag when lifted 
 
 
from supine and could roll over. He was dysmorphic with down-slanting palpebral 
fissures, slightly low set right ear and alternating divergent squint. Growth 
measurements were normal. Past investigations included normal karyotype, Fragile X 
and basic metabolic screening. He had a brain MRI which showed agenesis of the 
corpus callosum.  
At the age of almost 4 yr he had generalized hypotonia (deep tendon reflexes in the 
upper and the lower limbs were not elicited; plantars down going) and positional 
kyphosis. He had limited communication skills (single words only). He was mainly 
transported in a buggy but was able to use a standing frame for about 45 minutes a 
day. Since early childhood he had an anemia of unknown origin, which improved with 
iron supplements. 
At the age of 5.5 yr he was reviewed in the genetics clinic. He still had mild 
plagiocephaly. Hypotonia was improving; he had significant generalized joint laxity. 
Aged 7 yr he had a microarray which showed a maternally inherited duplication at 
Xq21.31 (chrX:86315153-86578362; hg18) containing no RefSeq genes within the 
minimum region and considered to be an innocent finding.  
At the last genetic review aged 12.7 yr his problems were global developmental 
impairment, ASD and ADHD, dysmorphic features and plagiocephaly, absent corpus 
callosum, generalized hypotonia, gastro-esophageal reflux with food regurgitation, 
recurrent loose stool and intermittent rectal mucosal prolapse, strabismus (wears 
corrective glasses). His height and weight were between the 2nd and 9th centile. He is 
regularly seen by the child adolescent mental health service. He attends a SEN school 
and due to social issues he is a child in care. 
He was enrolled as a singleton into the DDD project, which did not identify any 
pathogenic variants of known clinical significance. The heterozygous c.185C>T 
(p.Ser62Leu) variant in CDK8 was identified through DDD CAP#144 and subsequently 
confirmed on dideoxy-sequencing to be present in the subject and absent in his 
mother.  
 
  
 
 
Subject 9 
She is the 5th child of healthy, unrelated parents and was born at term following a 
normal pregnancy. She first came to medical attention at a few days of age with 
paroxysmal events consisting of eye rolling and limb jerking. These events were 
captured during an electroencephalogram (EEG) recording and were not felt to be 
epileptic. She had failed her neonatal hearing screen and was diagnosed with 
sensorineural hearing loss; profound on the right and moderate on the left. MRI brain 
examination at the time was normal other than some hippocampal asymmetry. 
Developmental delay was evident from 4 mo. A diagnosis of a seizure disorder was 
made by one year of age and Lamotrigine treatment started. A repeat MRI scan 
showed no progression of the previously observed changes but noted incomplete 
myelination. An additional diagnosis of a movement disorder consisting of tremor and 
dystonia was made by 4 yr. She continues with epileptic and non-epileptic paroxysmal 
events that are exacerbated by pyrexia. Investigations into her movement disorder 
have shown a low cerebrospinal fluid (CSF) homovanillic acid level, the significance 
of which is unclear. At 8 yr she has moderate delay in all developmental areas and a 
diagnosis of autism. She is well grown (OFC 25th centile), normally proportioned and 
has a facial appearance in keeping with that of her family. She exhibits abnormal 
posturing of all four limbs, an overt tremor of her upper limbs, but has normal power 
and deep tendon reflexes. She has mild peripheral joint hypermobility, but normal skin 
texture and elasticity. 
Array-CGH was normal. She was enrolled with her parents into the DDD and 100,000 
Genomes (WGS) projects, neither of which identified pathogenic variants of known 
clinical significance. The de novo c.291T>G (p.Phe97Leu) variant in CDK8 was 
identified through DDD CAP#144.  
 
Subject 10 
He was born at term following an unremarkable pregnancy. He is the third child of 
healthy unrelated parents. He had mild hyperbilirubinemia as a baby that did not 
require any treatment. There were no developmental concerns prior to the age of 1 
year. 
 
 
He was first assessed by the clinical genetics team at 5 yr, by which time he had global 
developmental delay and acquired microcephaly (OFC centiles at 3 mo on the 50th, at 
2 yr on the 25th and at 5 yr on the 2nd). He walked from around 2 yr, but remained 
unsteady and had a few single words of speech only with no ability to use Makaton or 
PECS cards. His receptive language abilities were a little better than this – assessed 
at the 24 mo level. His interactive and social skills had been assessed as at the 36 mo 
level. Other than his head circumference his general growth was in keeping with that 
of his family. He had generally been healthy, had a normal sleep pattern and there 
were no concerns regarding his hearing or vision. 
On examination he was well-proportioned with an unsteady broad-based gait. He was 
very active and had a friendly personality. He had a normal skull shape, his eyes were 
large and he had an open mouthed expression with mild prognathism and wide-
spaced teeth. His hands, feet and genitalia were normal. Skull radiographs did not 
show any evidence of craniosynostosis. 
Array-CGH showed a 220 kb deletion on chromosome 21q22.3 (chr21:44779709-
45001192, hg18) which was not felt to be of clinical significance. Methylation-specific 
analysis excluded common mechanisms of Angelman syndrome. DDD WES 
(performed as a singleton) identified three heterozygous variants in Developmental 
Disorders Genotype-to-Phenotype Database (DDG2P) genes (AFF c.1757G>A, 
p.Ser586Asn; LRP5 c.2900C>T, p.Pro967Leu; and SETBP1 c.3022C>A, 
p.Arg1008Ser), all of which were shown to have been inherited from one or other 
parent and not considered to be significant. The c.533G>A (p.Arg178Gln) variant in 
CDK8 was identified through DDD CAP#144, and confirmed by dideoxy-sequencing 
to be present in the subject and absent in both parents. Correct sample relationships 
were confirmed by analysis of 13 microsatellite markers. 
 
Subject 11 
This girl is the first child born to healthy, unrelated Sri Lankan parents. There was no 
family history of note. The pregnancy was uncomplicated. Birth weight was 2.6 kg at 
38 weeks’ gestation. She was readmitted at 1 week of age because of 
hyperbilirubinemia, which needed treatment with phototherapy and an exchange 
transfusion. This was attributed at the time to breast milk jaundice. She was noted to 
 
 
have a laryngeal stridor early in life; this resolved spontaneously after 1-2 yr. She was 
delayed in reaching her milestones, sitting at around 9-10 mo, and walking at around 
18 mo. She learned to ride a bike with stabilizers at the age of 6 yr.  
At the age of 3 yr she developed cyclical vomiting. This problem has persisted, and 
aged 12 yr she continues to be treated with flunarazine. She also takes salbutamol as 
required for treatment of asthma. She has had grommets inserted on two occasions 
for bilateral glue ear. 
Academically she is making reasonable progress, with a particular strength in reading. 
She has an excellent memory. At school she is good at history, geography and English 
literature, but struggles in maths. She does have some specific learning difficulties; at 
the age of 12 yr she is unable to draw a straight line using a ruler, and has difficulties 
drawing a table or graph. These skills are felt to be around 5 yr behind her 
chronological age.  
She is described as having a volatile personality. She can become easily disappointed 
if her requests are not met, and can be verbally aggressive at times; this tends to occur 
at home and be directed towards immediate family. At other times she is described as 
being sweet and charming. She can be overtalkative; non-verbal clues are often not 
understood. Anxiety can be an issue. Whilst she is not particularly hyperactive, and 
her attention span is reasonable when undertaking leisure activities such as reading, 
she is described as having some features compatible with ADHD. When she was 
younger her sleep was very restless, but she now sleeps well, although struggles to 
wake in the morning.  
Socially, she has several long term friends. She loves small babies and wants to be a 
kindergarten teacher. 
She was enrolled with her parents into the DDD (WES) project, which did not identify 
any pathogenic variants of known clinical significance. The de novo c.578T>G 
(p.Val193Gly) variant in CDK8 was identified through DDD CAP#144.  
 
  
 
 
Subject 12 
This boy, a 3.5-year-old Armenian/Caucasian male, was referred for clinical genetics 
assessment secondary to history of hypotonia. His parents initially became concerned 
during the first year of life owing to delay in achieving his gross motor milestones. As 
an infant he was bottle-fed because of inability to latch onto the breast, but otherwise 
he had no feeding difficulties and weight gain was satisfactory.  
He had been followed by the cardiology team secondary to a VSD, which has not 
required any surgical repair. His last echocardiogram, performed at the age of 6 mo 
showed one small 2 mm mid-muscular VSD and a second tiny anterior muscular VSD. 
He has passed his vision screening in his primary care physician's office, and his 
newborn hearing screen. A more recent hearing evaluation was non-contributory 
owing to lack of co-operation.  
He was diagnosed with autism aged 3 yr by his school psychologist and is currently 
enrolled in a special needs academic program at the pre-kindergarten level. He 
receives physical therapy, speech therapy, and occupational therapy. His growth 
measurements are normal. He is mildly dysmorphic, with a broad mouth, long philtrum 
which is well-defined, broad nasal tip, slightly down-slanted palpebral fissures and 
prominent ears; in addition, persistent fetal finger pads bilaterally and slight internal 
rotation of the medial malleoli were noted. He wears ankle-foot orthoses, which help 
with ambulation. He demonstrates a positive Gower maneuver when moving from a 
seated to standing position. Serum creatine kinase was normal. Fragile X and SNP 
chromosome microarray testing was normal. Clinical WES was performed on the 
parent-child trio by GeneDx and did not identify any known pathogenic variants; 
however the de novo c.669A>G (p.Ile223Met) substitution in CDK8 was highlighted as 
a VUS.  
 
 
 
Figure S1. Detection of CDK8, cyclin C, MED12 and MED13 in the purified CDK8 
Modules. Lysates from HEK293T cells transiently transfected with Myc-FLAG-tagged 
WT or mutant CDK8 constructs were used for immunoprecipitation using anti-FLAG 
antibody or mouse IgG isotype control antibody. The immunocomplexes were purified 
using magnetic beads with protein G. CDK8 was released by adding FLAG peptide 
and an aliquot of the eluted fraction was analyzed by automated capillary 
immunoassay system to detect CDK8, cyclin C, MED12 and MED13 (virtual blots at 
the top; relative quantifications from this experiment below).  
 
  
 
 
 
 
 Subject 1 Subject 2 Subject 3 Subjects 4-8 Subject 9 Subject 10 Subjects 11 Subject 12 
Genomic 
coordinate  
chr13:26254720 chr13:26254726 chr13:26254729 chr13:26337623 chr13:26349158 chr13:26385229 chr13:26385274 chr13:26393389 
DNA variant c.79G>C c.85C>G c.88G>A c.185C>T c.291T>G c.533G>A c.578T>G c.669A>G 
Protein 
change 
p.Val27Leu p.Arg29Gly p.Gly30Ser p.Ser62Leu p.Phe97Leu p.Arg178Gln p.Val193Gly p.Ile223Met 
Inheritance de novo de novo de novo de novoa de novo de novo de novo de novo 
MutationTaster disease causing disease causing disease causing disease causing disease causing disease causing disease causing disease causing 
SIFT damaging damaging damaging damaging tolerated damaging damaging damaging 
Polyphen-2 
possibly 
damaging 
probably 
damaging 
possibly 
damaging 
probably 
damaging 
benign 
probably 
damaging 
probably 
damaging 
probably 
damaging 
Genomic coordinates from GRCh38. Nomenclature is based on the NM_001260.2 transcript. aThis variant was demonstrated de 
novo in subjects 4-6 and was negative in the maternal samples of individuals 7 and 8, for whom paternal samples were unavailable. 
 
Table S1. Summary of CDK8 mutations and analyses of pathogenicity 
 
 
 
aPrimers for the exon 7 amplification include universal M13-tails (lower case). 
Table S4. Primers used for validation of the genomic variants in CDK8 
 
 
 
Primers for the directed mutagenesis Forward (5'-3') Reverse (5'-3') 
CDK8-SDM-V27L GGGCTGCAAAcTTGGCCGAGG TCGTATTCAAACAGGTCCTC 
CDK8-SDM-R29G CAAAGTTGGCgGAGGCACTTATG CAGCCCTCGTATTCAAAC 
CDK8-SDM-G30S AGTTGGCCGAaGCACTTATGG TTGCAGCCCTCGTATTCAAAC 
CDK8-SDM-S62L ATCTCTATGTtGGCATGTAGAG CCCAGTTCCTTCTATTTG 
CDK8-SDM-F97L GGCTTCTGTTgGACTATGCTG ACACCTTCCTATCAGCATG 
CDK8-SDM-R178Q GGCTTTGCCCaATTATTTAATTC CATGTCAGCAATTTTTACTC 
CDK8-SDM-V193G TTGGATCCAGgGGTTGTTACA ATCTGCTAAAGGCTTCAAAG 
CDK8-SDM-I223M TAGGGTGTATgTTTGCAGAAC TAGCCCAAATATCAATAGC 
CDK8-SDM-D173A AAAATTGCTGcCATGGGCTTTG TACTCTTCCTCGCTCAGG 
Primers for sequencing  Sequence (5'-3') 
CDK8-R1 TCGCTCAGGACCTTCACCC 
CDK8-F2 GAAGCCAGTTCAGTTACCTCG 
CDK8-F3 TGCAGCCTTATCAAGTATATGG 
 
Table S5. Mutagenesis and sequencing primers 
Primer Sequence (5'-3') Variants to screen 
CDK8-gDNA-Exon1-F CCTCAGAGGCTGTGACAATGG c.79G>C (p.V27L), 
c.85C>G (p.R29G), 
c.88G>A (p.G30S) CDK8-gDNA-Exon1-R GCGTCGAGGAAGTCAGAGCC 
CDK8-gDNA-Exon2-F ATCAAATAATGGGACTGGACTAGG 
c.185C>T (p.S62L) 
CDK8-gDNA-Exon2-R ACAATACAGAGCCTTATATAGTTGG 
CDK8-gDNA-Exon3-F TTTACCTGTGGGTTTGTATTGCC 
c.291T>G (p.F97L) 
CDK8-gDNA-Exon3-R AATACTCTAGCCTTCGTCATGCC 
CDK8-gDNA-Exon6-F GTAACAGTAATTTGAAGAGAATGG c.533G>A (R178Q), 
c.578T>G (p.V193G) CDK8-gDNA-Exon6-R TTAATTAGTTCTACTCACCAATAGC 
CDK8-gDNA-Exon7-Fa cacgacgttgtaaaacgacGGGTGGAGGGCATGGGAATA 
c.669A>G (p.I223M) 
CDK8-gDNA-Exon7-Ra ggataacaatttcacacaggACCTCTCCAACGAAGACATCTAAGT 
 
 
Supplemental Material and Methods 
 
Exome/genome sequencing and validation 
Trio whole genome sequencing of Subject 3 was performed by Complete Genomics 
(Mountain View, CA, USA), as described by Drmanac et al.6 Data were analyzed using 
cga tools version 1.6.0.43. A de novo disease model was tested, using the ‘calldiff 
script’ (Python script kindly provided by Complete Genomics) as described by Gilissen 
et al.7 Prioritization of variants was based on the minimal somatic score and manual 
curation of the variants.  
Trio exome sequencing of Subjects 1 and 5 (Utrecht cases) was performed as follows: 
exomes were enriched using the SureSelect XT Human All Exon V5 kit (Agilent) and 
sequenced in rapid run mode on the HiSeq2500 sequencing system (Illumina) at a 
mean target depth of 100x. The target was defined as all coding exons of UCSC and 
Ensembl +/- 20 bp intron flanks. At this depth ~95% of the target was covered at least 
15x. Reads were aligned to hg19 using BWA (BWA-MEM v0.7.5a) and variants were 
called using the GATK haplotype caller (v2.7-2). Detected variants were annotated, 
filtered and prioritized using the Bench NGS Lab platform (Cartagenia, Leuven, 
Belgium). Analysis was based upon a tiered approach. The first tier analyzed known 
intellectual disability genes. The second tier filtered for de novo variants and the last 
tier filtered for recessive variants. 
Trio exome sequencing of Subjects 2, 4, 6 and 12 (GeneDx cases) was performed as 
follows. Using genomic DNA from the proband and parents, the exonic regions and 
flanking splice junctions of the genome were captured using the Clinical Research 
Exome kit (Agilent Technologies, Santa Clara, CA) or the IDT xGen Exome Research 
Panel v1.0. Massively parallel sequencing was done on an Illumina system with 100 
bp or greater paired-end reads. Reads were aligned to human genome build 
GRCh37/hg19, and analyzed for sequence variants using a custom-developed 
analysis tool. Additional details of the sequencing technology and variant interpretation 
protocol have been described previously.8 The general assertion criteria for variant 
classification are publicly available on the GeneDx ClinVar submission page.  
 
 
Exome sequencing of Subjects 7, 8 and 10 (as singletons), and 9 and 11 (as trios) 
was performed as part of the DDD research study.9 Variant data were obtained as part 
of the approved Complementary Analysis Project #144 from Datafreeze 3, comprising 
7,833 trios and 1,792 singletons with undiagnosed developmental disorders, primarily 
developmental delay/learning disability.  
All the CDK8 variants were validated by dideoxy-sequencing of the probands, and all 
available parental samples were analyzed by exome/genome and/or dideoxy-
sequencing to assess inheritance of the CDK8 mutations. In subject 10, in whom the 
CDK8 variant was identified in a sample sequenced as a singleton, correct sample 
relationships of the trio were checked by demonstrating consistent inheritance of 13 
microsatellite loci (D1S2868, D3S1311, D4S403, D5S2027, D6S1610, D7S519, 
D9S158, D10S548, D11S898, D13S1265, D14S280, D16S415 and D18S474). The 
primers used for the PCR and dideoxy-sequencing validations of the genomic variants 
are listed in the Table S4.  
 
Protein alignment 
CDK8 protein sequences (FASTA format) from H. sapiens (human; P49336), M. 
musculus (mouse; Q8R3L8), X. tropicalis (western clawed frog; Q6P3N6), D. rerio 
(zebrafish; Q8JH47), D. melanogaster (fruit fly; Q9VT57), A. aegypti (mosquito; 
Q17IE8), C. elegans (nematode worm; P90866), and the human CDK19 protein 
sequence (Q9BWU1), the vertebrate paralogue of CDK8,10 were downloaded from 
Uniprot and a multiple protein sequence alignment was conducted by using Clustal 
Omega to evaluate the conservation of the CDK8 residues mutated in the subjects of 
this study.  
 
Structure preparation 
A homology model of CDK8 and cyclin C was generated in MOE 2015.1011 using the 
CDK8-cyclin C complex structure (PDB entry 4F7S)12 as template and the Uniprot13 
sequence identifier P49336 (CDK8 isoform 1) and P24863 (cyclin C isoform 1) to fill 
in gaps in CDK8 and remove artificial N-terminal residues in cyclin C in the input 
structure for molecular dynamics simulation. The homology model was aligned to the 
 
 
CDK9 structure (PDB entry 3BLQ)14 and ATP and Mg2+ were copied into the CDK8 
structure. The CDK8 complex (referring to the structure of CDK8 + ATP + Mg2+ + cyclin 
C) was prepared using the default settings of the protein preparation wizard in Maestro 
release 2017-2.15 Mutations were introduced using MOE. 
 
Simulation 
ATP topologies and parameters were generated using CGenFF webserver and 
cgenff_charmm2gmx.py python script (MacKerell lab webserver). The protein, solvent 
and ions were parameterized using the July 2017 update of the CHARMM36 force 
field16 in GROMACS version 2016.4.17-23 The simulations were performed in a cubic 
box with a minimum distance to the box boundaries of 10 Å, solvated with TIP3P24 
waters and neutralized with chloride ions. After minimization, the system was 
equilibrated with 100 ps runs using both NVT and NPT ensemble where N = 138057 
(CDK8 complex WT), 138059 (CDK8 complex p.Ser62Leu), 138055 (CDK8 complex 
p.Arg178Gln); T= 300 K; and P = 1 bar. Production simulations were run at least twice 
for 50 ns. If the variation between runs was large, a third run was included. Time steps 
of 2 fs were used and frames were saved every 10 ps. Temperature and pressure 
were maintained at 300 K and 1 bar and controlled by modified Berendsen 
thermostat25 and the Parrinello-Rahman26 barostat. The LINCS27 and Particle-Mesh 
Ewald28 algorithms were applied to define bond parameters and long-range 
electrostatics. A radius cut-off of 12 Å was applied to short-range van der Waals and 
electrostatic terms. The analysis was performed using the GROMACS analysis tools 
(rms, distance, hbond, covar, and anaeig) and figures were created using PyMOL.29 
 
Expression constructs 
The pCMV6-CDK8-Myc-FLAG (Origene, RC212592), containing the human cDNA 
open reading frame of human CDK8 (CDK8 WT) with C-terminal Myc-FLAG tags, was 
used for the functional analysis. The mutations in CDK8 were generated by 
mutagenesis PCR using the primers listed in the Table S5 and following the Q5-
Mutagenesis kit protocol (New England Biolabs). The previously described 
catalytically inactive CDK8 kinase-dead (p.Asp173Ala) mutant was used as control.30-
 
 
32 All constructs were verified by dideoxy-sequencing (R1, F2 and F3 primers in Table 
S5).  
 
Cell culture, transfection and immunoblotting 
The generation and full characterization of the SW620 CDK8/CDK19 double-knockout 
cells will be described in detail elsewhere.33 SW620 CDK8/CDK19 double knockout 
and HEK293T cells were cultured in DMEM supplemented with 10% fetal bovine 
serum (FBS), L-glutamine, and penicillin-streptomycin at 37°C under 5% CO2. For the 
functional assays transfections were performed using Lipofectamine 2000 (Thermo 
Fisher Scientific) according to the manufacturer’s instructions and cells were 
processed after 24 h. 
For immunoblotting, cells were collected and lysed in Cellytic M lysis buffer (Sigma-
Aldrich) containing protease (Complete, Sigma-Aldrich) and phosphatase (PhosStop, 
Sigma-Aldrich) inhibitors. The lysates were clarified by centrifugation at 15,000 g for 
15 min at 4°C and protein concentration was determined with the BCA Protein Assay 
Kit (Pierce, Thermo Scientific). All lysates were resolved on SDS-PAGE (Mini-Protean 
TGX 4-15% gradient gels, Biorad) and analyzed by Western blotting (WB) with specific 
antibodies. Primary antibodies used were anti-FLAG (F1804, Sigma-Aldrich), anti-
CDK8 (4106S, Cell Signaling), anti-phospho-STAT1-Ser727 (8826, Cell Signaling), 
anti-STAT1 (total) (9176, Cell Signaling), anti-cyclin C (A301-989A-M, Bethyl 
Cambridge Bioscience) and anti-Myc (2278T, Cell Signaling). GAPDH was detected 
as a loading control using the HRP-conjugated anti-GAPDH (3683, Cell Signaling). 
For anti‐phospho antibodies, the blocking reagent was 5% BSA in Tris-buffered saline, 
0.1% Tween 20 (T-TBS) instead of non-fat milk. For quantitative analysis, captured 
bands were analyzed with the Image J software (National Institutes of Health, 
Bethesda, MD).  
 
Immunoprecipitation, elution and thermal stability assay 
We previously showed that ligand binding to the Mediator kinases determined by 
biochemical assays with recombinant CDK8/CDK19 and cyclin C is not always 
recapitulated in intact cells, suggesting that the other components of the kinase 
 
 
module can influence CDK8 ligand-binding and activity.30 Therefore we determined 
whether the CDK8 kinase domain substitutions had caused structural changes and/or 
affected the ability to bind ATP using whole kinase Module complexes isolated from 
cells. HEK293T cells were transiently transfected, harvested after 24 h, washed with 
phosphate-buffered saline (PBS) and lysed in 220 µl of immunoprecipitation lysis 
buffer (50 mM HEPES [pH 7.3], 150 mM NaCl, 1 mM MgCl2, 1% Triton X100 [TX100]) 
containing protease (Complete, Sigma-Aldrich) and phosphatase (PhosStop, Sigma-
Aldrich) inhibitors. The lysates were centrifuged at 15,000 g for 15 min at 4°C and the 
supernatant was transferred to a new tube. An aliquot of 20 µl was saved from the 
supernatant to analyze (by WB) the total cell lysate fraction (TCL). The remaining 
lysates (200 µl) were processed for immunoprecipitation. All the incubations and 
washes were done in a rotator at 4°C. Lysates were incubated with 1 µg of anti-FLAG 
or the mAb IgG1 isotype control (5415S, Cell Signaling) antibody for 4 h. Then, 50 µl 
of Dynabeads Protein G (Invitrogen) were added and incubated for 2 h. Beads 
containing the immunocomplexes were washed three times with washing buffer (20 
mM HEPES [pH 7.3], 150 mM NaCl, 1 mM MgCl2, 0.2% TX100, supplemented with 
protease and phosphatase inhibitors). The immunoprecipitates were released from the 
magnetic beads by adding 200 µl of washing buffer containing 200 µg/mL of the FLAG 
peptide (F3290, Sigma-Aldrich) and saved as eluted fraction. An aliquot of the eluted 
fraction was evaluated by WB to demonstrate the presence of the immunoprecipitated 
CDK8 protein and its specific interactor cyclin C. The remaining volume of the eluted 
fractions was used for the thermal stability assay. Each elution was diluted with kinase 
buffer (Cell Signaling Technology) and with or without ATP at 2 mM (Thermo Fisher 
Scientific). Each sample (with or without ATP) was divided into 12 equal aliquots and 
heated individually at different temperatures determined between 50 to 82°C for 3 min, 
using a gradient thermal cycler, and followed by 3 min cooling at 21°C. The samples 
were then centrifuged for 20 min at 4°C at 18,000 g to separate the soluble proteins 
from the protein precipitated/degraded. The supernatant was collected and the protein 
content was analyzed by capillary immunoassay following the manufacturer’s protocol. 
The following antibodies were used when the capillary immunoassay system was 
employed: anti-CDK8 (4106S, Cell Signaling), anti-cyclin C (A301-989A, Bethyl 
Cambridge Bioscience), anti-MED12 (SC-5372, Santa-Cruz) and anti-MED13 
(Abcam, Ab76923). 
 
 
 
Statistical analysis 
Graphs and statistical analyses were conducted with Prism 5 (GraphPad). The 
quantification of immunoblot analysis was performed from five independent 
experiments. P-values were calculated using one-way ANOVA with Dunnett’s post hoc 
analysis. Values shown represent means ± standard error of the mean (SEM). In all 
figures, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001. 
 
Web Resources 
CGenFF webserver, https://cgenff.umaryland.edu/ 
GeneDx ClinVar submission page, http://www.ncbi.nlm.nih.gov/clinvar/submitters/26957/ 
MacKerell lab webserver, http://mackerell.umaryland.edu/ 
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